Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Depression jeopardizes HIV care - Healio

Depression jeopardizes HIV careHealioFrequent depression increases the risk that patients with HIV will miss primary care appointments, experience treatment failure and die, according to study findings published today in JAMA.

Published
Less than 1 hour ago
From
Google Alerts HIV
CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection

CytoDyn Inc. (OTC.QB:CYDY) reports the successful achievement of the primary endpoint in its CD02 Phase 2b/3 pivotal clinical trial with PRO 140 in combination with existing antiretroviral therapy (ART) in patients failing their current HIV therapy. The trial data show a statistically significant reduction in HIV-1 RNA viral load of greater than 0.5log with PRO 140 versus placebo. CytoDyn is developing PRO 140, a humanized CCR5 monoclonal antibody, to combat human immunodeficiency virus (HIV) infection and certain immunologic disorders.

Published
21 February 2018
From
CytoDyn press release
Mylan (MYL) Announces Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced receipt of tentative approval from the U.S. Food and Drug Administration (FDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg. The antiretroviral (ARV) will be immediately available in developing countries as a first-line regimen for people being treated for HIV/AIDS.

Published
20 February 2018
From
Mylan press release
Duterte's Condom Criticism Imperils Philippine HIV Fight

Philippine President Rodrigo Duterte, in a televised speech before Filipino women on February 13, 2018, urged them to not use condoms, comparing usage to eating wrapped candy.

Published
20 February 2018
From
Human Rights Watch
Sources of Information for Self-care Among Patients Living with HIV

The purpose of this study was “to identify the helpful information sources for self-care strategies, including Common sense/Self-experience, Healthcare professional, Internet, Literature, Multiple, Social Support and TV ads.

Published
20 February 2018
From
MD Magazine
Zambia: HIV deaths on treatment underestimated

People with HIV in Zambia were at least ten times more likely to die in the first two years after starting antiretroviral treatment than European

Published
14 February 2018
By
Keith Alcorn
Darunavir/ritonavir most durable boosted protease inhibitor in European patients, especially those switching treatment for any reason

Darunavir/ritonavir is the most durable boosted protease inhibitor for antiretroviral (ART)-experienced patients, investigators from the EuroSIDA cohort report in HIV Medicine. Patients switching treatment to

Published
13 February 2018
By
Michael Carter
Communication skills training for healthcare workers improves HIV treatment adherence

People with HIV in Tanzania were more likely to report problems with non-adherence to antiretroviral treatment after their healthcare providers underwent training in patient-centred communication

Published
09 February 2018
By
Keith Alcorn
US regulators approve new HIV combo pill containing bictegravir

The US Food and Drug Administration (FDA) yesterday approved Biktarvy, Gilead Sciences' new single tablet antiretroviral regimen containing the HIV integrase inhibitor bictegravir, which was highly effective

Published
08 February 2018
By
Liz Highleyman
ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment

Today ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the start of a phase III study designed to establish if adults with HIV-1 with current virologic suppression on a tenofovir alafenamide fumarate (TAF)-based regimen of at least three drugs are able to maintain viral suppression upon switching to a two-drug regimen (2DR) of dolutegravir (TIVICAY) and lamivudine (EPIVIR).

Published
08 February 2018
From
ViiV press release
← First12345...461Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.